Semaglutide (GLP-1)
99% Pure | USA Made | Multi Dose
Semaglutide is a GLP-1 receptor agonist that helps regulate appetite and blood sugar levels, supporting sustainable weight management when combined with diet and exercise.
Dosage
$250
Pairs well with
Bacteriostatic Water
Required for reconstitution
$12
Note: Peptides are not ready to use. Must purchase BAC water for reconstitution.
What makes Semaglutide (GLP-1) exceptional
Every treatment in our catalog is physician-reviewed and pharmacy-compounded. Here's why Semaglutide (GLP-1) stands out.
Acts on GLP-1 receptors in the brain to naturally reduce hunger and food cravings
What is Semaglutide (GLP-1)?
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the natural incretin hormone to regulate appetite, blood sugar, and metabolic function. Originally developed for type 2 diabetes management, it has demonstrated transformative results in clinical weight management trials, helping patients achieve sustainable fat loss through appetite modulation and improved insulin sensitivity.
0.25–2.4mg weekly · Subcutaneous injection
Administered under physician guidance
Why choose Semaglutide (GLP-1)?
Semaglutide has become the gold standard in peptide-based weight management. Under physician supervision, it delivers:
Clinically proven average weight loss of 15-20% body weight
Powerful appetite suppression through central nervous system signaling
Improved glycemic control and insulin sensitivity
Cardiovascular risk reduction benefits
Convenient once-weekly dosing protocol
What sets Semaglutide (GLP-1) apart
Semaglutide stands apart through its dual mechanism of action: it simultaneously reduces appetite via hypothalamic signaling while improving metabolic efficiency at the cellular level. Unlike crash diets or stimulant-based approaches, it recalibrates the body’s weight set-point for sustainable, long-term results that persist when combined with lifestyle changes.
Backed by research
Peer-reviewed studies supporting Semaglutide (GLP-1) treatment protocols.
STEP 1 Trial — Semaglutide 2.4mg for Weight Management
Participants lost an average of 14.9% body weight over 68 weeks compared to 2.4% with placebo.
Semaglutide and Cardiovascular Outcomes
Reduced risk of major cardiovascular events by 20% in overweight adults without diabetes.
Pairs well with
Complementary treatments often used alongside Semaglutide (GLP-1).
Ready to start your treatment?
All orders require physician approval. You're only charged if approved.